deltatrials
Completed PHASE2 NCT00041132

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma
Interventions cyclophosphamide cytarabine dexamethasone doxorubicin filgrastim leucovorin methotrexate rituximab vincristine
Updated 6 times since 2017 Last updated: Oct 3, 2012 Started: Sep 30, 2002 Primary completion: Nov 30, 2007 Completion: Jun 30, 2011

Listed as NCT00041132, this PHASE2 trial focuses on Lymphoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — May 2023 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.